Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5971548 | 1.00 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1 | |
| SCHEMBL227362 | 1.00 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1 | |
| SCHEMBL589317 | 1.00 | CYSLTR2 (0.75) | CYSLTR2CYSLTR1 | |
| SCHEMBL3263816 | 0.94 | CYSLTR2 (0.69) | CYSLTR2CYSLTR1 | |
| SCHEMBL3263812 | 0.94 | CYSLTR2 (0.69) | CYSLTR2CYSLTR1 | |
| SCHEMBL2125181 | 0.94 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1 | |
| SCHEMBL2125184 | 0.94 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1 | |
| SCHEMBL2124624 | 0.93 | CYSLTR2 (0.66) | CYSLTR2CYSLTR1 | |
| SCHEMBL5601096 | 0.89 | CYSLTR1 (0.66) | CYSLTR2CYSLTR1 | |
| SCHEMBL5200473 | 0.85 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | US | claimed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | claimed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2020-10-22 | — | — | US | disclosed |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-18 | — | — | US | disclosed |
| EP-3643309-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-2878297-B1 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INT (DE) | 2020-03-25 | — | — | EP | disclosed |
| EP-2326374-B1 | INHALER | BOEHRINGER INGELHEIM INT (DE) | 2020-03-04 | — | — | EP | disclosed |
| WO-2003043980-A1 | AZETIDINYL DIAMINES USEFUL AS LIGANDS OF THE NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003039469-A2 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
| US-20030073690-A1 | High affinity ligands for nociceptin receptor ORL-1 | MERCK SHARP & DOHME CORP. | 2003-04-17 | — | — | US | disclosed |
| EP-1258244-A1 | High affinity ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6455527-B2 | ANALGESICSANALGESICS, ANXIOLYTIC AGENTS, ANTHISTAMINES, ANTIDEPRESSANTS | SCHERING CORPORATION | 2002-09-24 | — | — | US | disclosed |
| WO-2002067938-A2 | TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | SCHERING CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
| US-20020061902-A1 | Treatment method | SCHERING CORPORATION | 2002-05-23 | — | — | US | disclosed |
| US-20010011092-A1 | High affinity ligands for nociceptin receptor ORL-1 | MERCK SHARP & DOHME CORP. | 2001-08-02 | — | — | US | disclosed |
| US-6262066-B1 | High affinity ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CYSLTR2 19/4885CYSLTR1 23/4885 |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | CBS, DHPS, TPMT | CYSLTR2 25/4885CYSLTR1 8/4885 |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | ADRB2, ADRA2A, ADRB1 | CYSLTR2 157/4885CYSLTR1 216/4885 |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | CYSLTR2 242/4885CYSLTR1 101/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CYSLTR2 19/4885CYSLTR1 23/4885 |
| US-20030073690-A1 | High affinity ligands for nociceptin receptor ORL-1 | OPRL1, OGFRL1, OPRD1 | CYSLTR2 54/4885CYSLTR1 26/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | CYSLTR2 221/4885CYSLTR1 142/4885 |
| US-20010011092-A1 | High affinity ligands for nociceptin receptor ORL-1 | OPRL1, OGFRL1, OPRD1 | CYSLTR2 54/4885CYSLTR1 26/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | CYSLTR2 21/4885CYSLTR1 36/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CYSLTR2 19/4885CYSLTR1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.